Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.91, $0.35 better than the analyst estimate of $1.56. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.21 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.